{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:35:04Z","timestamp":1787895304556,"version":"build-2784847793"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The aim of the study was to identify, interpret, and compare the current perspectives of regulatory agencies in six member countries of BRICS-TM (Brazil, Russia, India, China, South Africa, Turkey, and Mexico) on the different criteria used for biosimilar development and marketing authorisation process.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A semi-quantitative questionnaire was developed covering the organisation of agency, biosimilar development criteria and marketing authorisation process and sent to seven regulatory agencies covering the BRICS-TM countries. All data was kept anonymous and confidential. Data processing and analysis was carried out; descriptive statistics were used for quantitative data and content analysis was employed to generate themes for qualitative data.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Out of the seven regulatory agencies included in the study, six representatives provided the responses. The perspectives of these six regulatory agencies varied on a number of aspects relating to the review criteria for biosimilar development and licencing process. The most prevalent model for data assessment is the \u201cfull review\u201d of a marketing authorisation application. There is lack of a standard approach across the agencies on sourcing of the reference biological product, <jats:italic>in vivo<\/jats:italic> toxicity studies and confirmatory clinical studies. Most agencies restrict interaction with biosimilar developers and any scientific advice is non-binding. The marketing authorisation approval depends on scientific assessment of the dossier, sample analysis and GMP certification. The agencies do not issue any public assessment report specifying the summary basis of biosimilar approval.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Regulatory agencies across the six emerging economies are steadily improving the regulatory mechanism in the area of biosimilars. However, there remains scope for increasing the effectiveness and efficiency of the processes by encouraging open and transparent interaction with developers, adopting a flexible approach toward accepting advanced analytical data in lieu of clinical studies and enhancing regulatory reliance amongst agencies. This will help to simplify the new biosimilar development programmes and make them more cost-effective.<\/jats:p>","DOI":"10.3389\/fmed.2021.726660","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T10:49:22Z","timestamp":1631184562000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Current Regulatory Requirements for Biosimilars in Six Member Countries of BRICS-TM: Challenges and Opportunities"],"prefix":"10.3389","volume":"8","author":[{"given":"Hasumati","family":"Rahalkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Mendes Lima","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitralekha","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Mayra","family":"Perez-Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Lopez-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Salek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9627.1000243","article-title":"Biosimilars and emerging markets: historical and bioethical considerations","volume":"6","author":"Leintz","year":"2015","journal-title":"J Clin Res Bioeth"},{"key":"B2","unstructured":"IQVIAInstitute\n          The Global Use of Medicine in 2019 and Outlook to 2023: Forecasts and Areas to Watch2019"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom9090410","article-title":"The breakthrough of biosimilars: a twist in the narrative of biological therapy","volume":"9","author":"Kabir","year":"2019","journal-title":"Biomolecules."},{"key":"B4","unstructured":"ChenY\n            LehmannA\n            da SilvaJS\n          What's next for biosimilars in emerging markets?2019"},{"key":"B5","unstructured":"Medicines regulation: comparison of medicines legislation in the East African Community567\n            SilloHB\n          WHO Drug Information.302016"},{"key":"B6","unstructured":"GenevaEssential medicines and health products: Medicines regulatory support2019"},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/BS.S44052","article-title":"Global regulatory landscape of biosimilars: emerging and established market perspectives","volume":"5","author":"Krishnan","year":"2015","journal-title":"Biosimilars"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2018.01079","article-title":"Quality, non-clinical and clinical considerations for biosimilar monoclonal antibody development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines","volume":"9","author":"Rahalkar","year":"2018","journal-title":"Front Pharmacol."},{"key":"B9","unstructured":"Improving Access and Affordability for Biopharmaceuticals in Emerging Markets114IFC Global Private Health Care Conference2019"},{"key":"B10","unstructured":"XII BRICS Summit to Be Held on 17 November 2020 Via Videoconference2020"},{"key":"B11","unstructured":"HindustanTimes\n          Virtual BRICS Summit on Nov 17; PM Modi, Xi set for a face-off: Hindustan Times2020"},{"key":"B12","unstructured":"ChaudhuryDR\n          BRICS Summit to be held virtually on November 17 2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/009286150904300314","article-title":"Emerging markets and emerging agencies: a comparative study of how key regulatory agencies in Asia, Latin America, the Middle East, and Africa are developing regulatory processes and review models for new medicinal products","volume":"43","author":"McAuslane","year":"2009","journal-title":"Drug Inform J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40259-017-0218-5","article-title":"Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community","volume":"31","author":"Markus","year":"2017","journal-title":"BioDrugs."},{"key":"B15","unstructured":"140GenevaAnnex 2: Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)2013"},{"key":"B16","unstructured":"CPD with Regulatory RapporteurBiosimilar products: Regulatory complexities and challenges of biosimilars2019"},{"key":"B17","unstructured":"19LondonGuideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues (revision 1) EMA\/CHMP\/BWP\/247713\/20122014"},{"key":"B18","unstructured":"153New DelhiGuidelines on similar biologics: Regulatory Requirements for Marketing Authorization in India2016"},{"key":"B19","unstructured":"113LondonGuideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues EMEA\/CHMP\/BMWP\/42832\/2005 Rev12014"},{"key":"B20","unstructured":"131GenevaGuidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2)2009"},{"key":"B21","unstructured":"121Rockville, MDFormal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products: Guidance for Industry2018"},{"key":"B22","unstructured":"123LondonEuropean Medicines Agency Guidance for Applicants Seeking Scientific Advice and Protocol Assistance EMA\/4260\/2001 Rev. 102020"},{"key":"B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fphar.2018.00009","article-title":"The Turkish medicines and medical devices agency: comparison of its registration process with Australia, Canada, Saudi Arabia, and Singapore","volume":"9","author":"Mashaki Ceyhan","year":"2018","journal-title":"Front Pharmacol."},{"key":"B24","unstructured":"WelchAR\n          The Evolution Of Russia's Biosimilar Regulatory Pathway Biosimilar Development2017"},{"key":"B25","doi-asserted-by":"publisher","first-page":"711361","DOI":"10.3389\/fphar.2021.711361","article-title":"Comparison of BRICS-TM countries' biosimilar regulatory frameworks with Australia, Canada and Switzerland: benchmarking best practices","volume":"12","author":"Rahalkar","year":"2021","journal-title":"Front Pharmacol"},{"key":"B26","unstructured":"13GenevaIGBA Reflection on Regulatory System Strengthening for Biosimilar Medicines2020"},{"key":"B27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/nyas.14522","article-title":"Regulatory challenges with biosimilars: an update from 20 countries","volume":"1491","author":"Kang","year":"2021","journal-title":"Ann N Y Acad Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11926-016-0564-1","article-title":"The regulation of biosimilars in Latin America","volume":"18","author":"Garcia","year":"2016","journal-title":"Curr Rheumatol Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bjophthalmol-2019-314443","article-title":"Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective","volume":"104","author":"Sharma","year":"2020","journal-title":"Br J Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/bjd.15756","article-title":"Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice","volume":"177","author":"Cohen","year":"2017","journal-title":"Br J Dermatol."},{"key":"B31","unstructured":"FerreriD\n          AJMCWHO Survey Identifies Global Regulatory Challenges for Biosimilars2020"},{"key":"B32","unstructured":"Expression of interest: SADC medicines regulatory worksharing, Zazibona collaborative process2019"},{"key":"B33","unstructured":"Collaborating Centres by Member State2021"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-021-00395-8","article-title":"Challenges faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM countries: An Exploratory Study","author":"Rahalkar","year":"2021","journal-title":"Pharm Med"},{"key":"B35","unstructured":"Biosimilars & Biologics2020"},{"key":"B36","unstructured":"16GenevaDeveloping a Regulatory Policy Framework Supporting Biosimilar Competition: The Opportunity for Tailored Clinical Biosimilar Development2020"},{"key":"B37","unstructured":"Better regulation of medicines means stronger regional health security110\n            BallD\n            RothS\n            ParryJ\n          ADB Briefs542016"},{"key":"B38","unstructured":"LondonTailored scientific advice to support step-by-step development of new biosimilars2016"},{"key":"B39","volume-title":"Regulating Medicines in a Globalized World: The Need for Increased Reliance Among Regulators","year":"2020"},{"key":"B40","unstructured":"WelchAR\n          6 Tips For Navigating Emerging Market Biosimilar Regulations Pennsylvania: Biosimilar Development.2016"},{"key":"B41","unstructured":"19GenevaGuidance- GMP Inspection reliance2018"},{"key":"B42","unstructured":"Brazil-ANVISA Resolution RDC 346\/2020 with Alternative GMP Auditing (Good Manufacturing Practice) Requirements Due to COVID-19 Epidemic.2020"},{"key":"B43","unstructured":"Brazil-ANVISA Resolution RDC 348\/2020 with Alternative Procedures for Registration of Medicines, Biological Products and In Vitro Diagnostic Products Due to COVID-19 Epidemic.2020"},{"key":"B44","unstructured":"The Russian regulator is developing a remote GMP inspection process in connection with the pandemic.2020"},{"key":"B45","unstructured":"New DelhiThe New Drugs and Clinical Trials Rules, The Gazette of India, Part II-Section 3-Subsection (i). Notification.2019"},{"key":"B46","unstructured":"New DelhiOffice Memorandum: Rapid response framework for COVID-19 to deal with applications develop for vaccines, diagnostics, prophylatics and therapeutics- reg2020"},{"key":"B47","unstructured":"SAHPRA policy on conduct of clinical trials of health products during the current COVID-19 pandemic2020"},{"key":"B48","unstructured":"Kili\u00e7S\n            \u00dcnalN\n          COVID-19: Turkey to Extend Measures for GMP Inspections and Certification.2021"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.726660\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T10:49:45Z","timestamp":1631184585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.726660\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":48,"alternative-id":["10.3389\/fmed.2021.726660"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.726660","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]},"article-number":"726660"}}